摘要
Robak, LA, Jansen, IE, Rooij, J et al. Excessive burden of lysosomal storage disorder gene variants in Parkinson's disease. Brain. 2017 Dec 1; 140( 12): 3191- 3203. Mutations in the glucocerebrosidase gene (GBA) cause autosomal recessive Gaucher's disease. The connection between the GBA gene and Parkinson's disease (PD) was recently recognized; GBA mutations impair alpha-synuclein clearance,3 and prompt a search for any relationship between PD and other lysosomal disorders (LSDs).1 Mutations in alpha-synuclein, LRRK2, VPS35, PINK1, DJ1 are associated with mitochondrial and endo-lysosomal dysfunction.2 Both mitochondria and lysosomes are involved in lipid and protein trafficking and metabolism.2 Moreover, mutations in LSD genes may lead to PD by altering lysosomal activity resulting in alpha-synuclein accumulation and disrupting the transport of highly specific hydrolases within dopaminergic neurons, thus impairing mitochondrial quality control mechanisms. Homozygous and heterozygous GBA mutations are the largest genetic risk factor for PD (5-20 increased risk).3 While there are multiple studies involving GBA in PD, there are few studies of other lysosomal disorders.1 The small number of studies of other LSDs may be because patients with severe childhood LSDs die before PD symptoms appear, or that once PD is diagnosed metabolic tests are not done, resulting in few patients available for study.4 However, features of parkinsonism occur in some metabolic disorders, including Niemann Pick's disease, lipogranulomatosis, or ceroid lipofuscinosis.4 Robak and colleagues recently assessed the mutation burden of other LSD genes and PD susceptibility by using the largest available whole exome sequencing (WES) database (1156 PD patients and 1679 controls). The results were replicated in two independent cohorts (PPMI and NeuroX) of over 7000 PD patients and more than 6000 controls.1 Fifty-four lysosomal genes were evaluated.1 The authors confirmed the known PD association at the Gaucher's and Niemann Pick's loci. They also showed association of three novel loci including cathepsin D gene (CTSD) associated with ceroid lipofuscinosis (seizures, myoclonus, ataxia, blindness),5 solute carrier family 17 member 5 (SLC17A5) associated with Salla disease (developmental delay, seizures, ataxia, spasticity, athetosis),6 and N-acylsphingosine amidohydrolase (ASAH1) associated with Farber lipogranulomatosis (subcutaneous nodules, deformed joints, hoarseness) with PD.1 Over half of PD patients had at least one mutation in a LSD gene. Roughly one-fifth carried multiple mutations. Thus, the susceptibility to PD increased in the presence of several lysosomal genetic risk factors. Importantly, the association remained significant even following GBA exclusion.1 The three novel risk factors identified by Robak et al. have a role in lysosomal transport (SLC17A5), ceramide metabolism (ASAH1), and in alpha-synuclein degradation (CTSD is a lysosomal proteinase).1 In the near future, we are hopeful that explicit disease-modifying therapies will be developed for specific genetic forms of PD such as LRRK2 kinase inhibitors, knockdown therapy for SNCA duplications, parkin mitochondrial enhancers, or enzymatic compounds capable of crossing brain-blood barrier in GBA carriers (such as over the counter medication for respiratory conditions facilitating lysosomal exocitosis-ambroxol). The additional loci discovered in this study and the identification of an increased burden of lysosomal genetic risk factors in PD may increase our understanding of the interplay between mitochondria and lysosomes (two closely related cell housekeeping regulators), and provide further insight into PD pathogenesis. Thus hopefully leading to the development of innovative precision therapies for PD. 1. Research Project: A. Conception, B. Organization, C. Execution; 2. Statistical Analysis: A. Design, B. Execution, C. Review and Critique; 3. Manuscript Preparation: A. Writing the First Draft, B. Review and Critique. D.A.O.: 3A T.L.: 3B Ethical Compliance Statement: We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflict of Interest: No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work. Financial Disclosures for the previous 12 months: The authors declare that there are no additional disclosures to report.